Welcome to Lab Test Consult

You can log in and post your comments

Share your knowledge and experience!

Member Login
Lost your password?

LipoScience seeks regulatory approval for test

January 6, 2012

LipoScience, which had 171 employees as of June 30, announced today that it is seeking permission to market the device from the Food and Drug Administration. The company previously reported in a securities filing that it hopes to win regulatory approval in time to begin selling the device later this year.

CEO Richard O. Brajer said in a prepared statement that decentralizing administration of the test would have several benefits, including significantly reducing the turnaround time for test results in some cases.

Company officials couldn’t immediately be reached for additional comment.

LipoScience’s ultimate goal is to replace traditional cholesterol tests. In 10 clinical trials involving more than 48,000 patients, the LipoProfile test has proven to be a better indicator of heart disease than traditional tests, according to the company. The LipoProfile test measures the quantity and size of lipoprotein particles, which carry cholesterol, in the blood.

Selling the Vantera device to other labs could conceivably raise the profile of LipoScience’s test. “There is not currently widespread awareness of the NMR LipoProfile test among clinicians, even though the test has been available since 1999,” the company declared in a securities filing.

In June the privately held company disclosed in a filing with the Securities and Exchange Commission that it hopes to raise $86.25 million in an initial public offering of stock. The company first filed IPO plans in 2002, but subsequently scrapped them.

At the end of September the company filed updated financial documents with the SEC, a sign that it remains interested in pushing ahead with its latest IPO plan.

LipoScience reported that over the fist six months of the year it generated $21.7 million in revenue, up 12 percent from a year earlier. The company lost $809,000 during that span, down from a $1.1 million profit, as it boosted research-and-development expenses by 15 percent and expanded its sales and marketing staff from 50 to 69.

Article source: http://newsobserver.com/2012/01/05/1755533/liposcience-seeks-regulatory-approval.html


Related posts:

  1. LipoScience upgrades test
  2. BD Gets FDA OK, CLIA Waiver for Flu Test
  3. New York State Clears Rosetta Genomics’ Array-based Cancer of Unknown Primary Test
  4. MDxHealth Q4 Revenues Down 43 Percent, Continues Preparation for Prostate Cancer Test Launch
  5. Pinpoint MD nears $1.5 million for digital diagnostics platform
  6. FDA Clears Dako’s Companion Dx for Herceptin
  7. LifeCodexx to Expand Lab for Trisomy 21 Test
  8. Novartis gains European Commission approval for Rasitrio┬«, a Rasilez-based triple combination pill to treat high blood …
  9. FDA Revokes Approval of Avastin for Breast Cancer
  10. OPKO Health Announces Commencement of U.S. Clinical Trial for Point-of-Care Prostate Specific Antigen Test


New post


January 2019
« Aug    


Recent comments

    Contact Sign In

    Email Marketing You Can Trust